Therefore, as an inhibitor of SREBP1, fatostatin can improve the sensitivity of endometrial cancer to progesterone and reverse progesterone resistance by suppressing SREBP1/NF-κB signaling [141]. The gene discussed is SREBF1; the disease is endometrial cancer.